Page 174 - 2019_09-HaematologicaMondo-web

S.C. Oostindie et al.
High Resolution Mapping of the Binding
Site on Human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fcgamma R. J Biol Chem. 2000;276(9):6591-6604.
11. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc Receptors. Cancer Res. 2007;67(18):8882-8890.
12. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activ- ity to recruit complement. J Immunol. 2001;166(4):2571-2575.
13. Natsume A, In M, Takamura H, et al. Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities. Cancer Res. 2008;68(10):3863-3872.
14. Melis JPM, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PWHI. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67(2, Part A):117-130.
15. Diebolder CA, Beurskens FJ, de Jong RN, et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. Science. 2014;343(6176):1260-1263.
16. de Jong RN, Beurskens FJ, Verploegen S, et al. A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen- Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biol. 2016; 14(1):e1002344.
17. Lindorfer MA, Cook EM, Tupitza JC, et al. Real-time analysis of the detailed sequence of cellular events in mAb-mediated com- plement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Mol Immunol. 2016;70:13-23.
18. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800.
19. Dechant M, Weisner W, Berger S, et al. Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies. Cancer Res. 2008;68(13):4998-5003.
20. Klausz K, Berger S, Lammerts van Bueren JJ, et al. Complement mediated tumor specific cell lysis by antibody combinations target- ing epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Cancer Sci. 2011;102(10):1761-1768.
21. Link MP, Bindl J, Meeker TC, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol.
1986;137(9):3013-3018.
22. Schwartz-Albiez R, Dörken B, Hofmann
W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and sub- cellular expression of an extensively glyco- sylated glycoprotein. J Immunol. 1988; 140(3):905-914.
23. Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500-3510.
24. Heider K-H, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159- 4168.
25. Pereira DS, Guevara CI, Jin L, et al. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015; 14(7):1650-1660.
26. Repetto-Llamazares AHV, Larsen RH, Patzke S, et al. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS One. 2015;10(6):e0128816.
27. Zhao XB, Biswas S, Mone A, et al. Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B- Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells. Blood. 2004;104(11):2515.
28. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal anti- body. Science. 1994;266(5187):1024-1027.
29. Deckert. J. CD37-binding molecules and immunoconjugates thereof. WO 2011/112978A1.(2011).
30. Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma J-J, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 2014;65(1):5-10.
31. Cook EM, Lindorfer MA, van der Horst H, et al. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting
Conditions. J Immunol. 2016;197(5):1762-
1775.
32. Cragg MS, Morgan SM, Chan HTC, et al.
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052.
33. Chou T-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol Rev. 2006;58(3):621-681.
34. Beckwith KA, Byrd JC, Muthusamy N. Tetraspanins as therapeutic targets in hematological malignancy: a concise review. Front Physiol. 2015;6:91.
35. Teo EC-y, Chew Y, Phipps C. A review of monoclonal antibody therapies in lym- phoma. Crit Rev Oncol Hematol. 2016;97:72-84.
36. Xu-Monette ZY, Li L, Byrd JC, et al. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk predic- tion in diffuse large B-cell lymphoma. Blood. 2016;128(26):3083-3100.
37. de Winde CM, Elfrink S, van Spriel AB. Novel Insights into Membrane Targeting of B Cell Lymphoma. Trends Cancer. 2017;3(6):442-453.
38. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6(10):801-811.
39. Simons K, Sampaio JL. Membrane Organization and Lipid Rafts. Cold Spring Harb Perspect Biol. 2011;3(10):a004697.
40. Hicks SW, Lai KC, Gavrilescu LC, et al. The Antitumor Activity of IMGN529, a CD37- Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia (New York, NY). 2017;19(9):661-671.
41. Repetto-Llamazares AHV, Malenge MM, O'Shea A, et al. Combination of (177) Lu- lilotomab with rituximab significantly improves the therapeutic outcome in preclin- ical models of non-Hodgkin's lymphoma. Eur J Haematol. 2018;101(4):522-531.
42. Dienstmann R, Patnaik A, Garcia- Carbonero R, et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015;5(6):598-609.
43. Jacobsen HJ, Poulsen TT, Dahlman A, et al. Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clin Cancer Res. 2015;21(18):4110-4122.
1852
haematologica | 2019; 104(9)